Background And Receptor Mechanism — Research Overview

By Editorial Desk · published 2026-06-03 · last reviewed 2026-07-13 · Info

The short version of ghrelin receptor fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-07-13 and is reviewed periodically as new material appears.

Background And Receptor Mechanism

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Ipamorelin Background and Receptor Selectivity

Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.

Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.

Ipamorelin at a glance

背景与分子特征

在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。

从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。

Related pages on this site

• Connected casebook
• Clear overview
• Comprehensive workbook
• Measured briefing
• Gradual workbook
• Focused workbook
• Clear workbook
• Automated handbook

Receptor Selectivity and Secretagogue Signaling

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Signal transduction begins when the peptide binds GHSR-1a on pituitary somatotrophs. The receptor couples to Gq/11 proteins, activating phospholipase C, which cleaves phosphatidylinositol bisphosphate into inositol trisphosphate and diacylglycerol. Inositol trisphosphate releases calcium from intracellular stores, and the resulting rise in cytosolic calcium drives growth hormone vesicle fusion. Concurrent Gs coupling and cyclic AMP elevation have also been reported, and the relative contribution of each arm to the overall secretory response is not fully settled.

Reference notes

== Personal life == Hird married Tania Poynton on 11 October 1997. Around the time of the marriage, Poynton was working as a lawyer at legal firm Corrs Chambers Westgarth, where she remained until 2002. The couple have since separated. Hird shares four children with Tania: a daughter and three sons. One of his sons, Thomas Hird, was signed as a category B rookie at Essendon in 2019 and was delisted by Essendon in 2022. Tom Hird now plays for the Port Melbourne Football Club in the Victorian Football League. Hird's paternal grandfather, the late Allan Hird, Sr., was a notable player for and president of the Essendon Football Club, and his father, Allan Hird, Jr., had a brief playing career with Essendon. Hird completed a bachelor's degree in civil engineering in 1998 and worked in that capacity as a consultant on the CityLink project. He has also spent time working for a stockbroking firm and is an active partner in Gemba, a sports marketing and media consultancy firm based in Melbourne. He is the founder and managing director of Euree Asset Management, where he currently works. On 5 January 2017, Hird was taken to a private hospital following a drug overdose and suspected suicide attempt and was subsequently transferred to a specialist mental health care facility for further care and treatment. On 28 November 2018, Hird was hit by a car when cycling in Richmond.

=== Mindfulness === Langer is known for her contributions to the study of mindfulness and of mindless behaviour, which provided the basis for many studies focused on individual differences in unconscious behavior and decision-making processes in humans. Although she initially studied meditation as well, she grew to focus more on the study of mindfulness without meditation. In 1989, she published Mindfulness, arguing for the widespread influence and application of mindfulness to business, education, science, art, and interpersonal relationships, and she became known as the "mother of mindfulness". Langer defines mindfulness as "the simple act of noticing new things." The Langer Mindfulness Scale aims to proxy for measures of this form of mindfulness. Langer says that mindfulness can help teach that "uncertainty is the rule rather than the exception."

The three substrates of this enzyme are formaldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are formic acid, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is formaldehyde:NAD+ oxidoreductase. Other names in common use include NAD+-linked formaldehyde dehydrogenase, s-nitrosoglutathione reductase (GSNO reductase) and NAD+-dependent formaldehyde dehydrogenase. This enzyme participates in methane metabolism.

=== Computational prediction of protein–protein interactions === The experimental detection and characterization of PPIs is labor-intensive and time-consuming. However, many PPIs can be also predicted computationally, usually using experimental data as a starting point. However, methods have also been developed that allow the prediction of PPI de novo, that is without prior evidence for these interactions.

A typical APCI source usually consists of three main parts: a sample inlet, a corona discharge needle, and an ion transfer region under intermediate pressure. In the case of the heated nebulizer inlet from an LC, as shown in the figure, the eluate flows at 0.2 to 2.0 mL/min into a pneumatic nebulizer which creates a mist of fine droplets. Droplets are vaporized by impact with the heated walls at 350–500 °C and carried by the nebulizer gas and an auxiliary gas into the ion molecule reaction region between the corona electrode and the exit counter-electrode. A constant current of 2–5 microamps is maintained from the corona needle. Sample ions are produced by ion-molecule reactions (as described below), and pass through a small orifice or tube into the ion transfer region leading to the mass spectrometer. Various geometries of ion source are possible, depending on application. When used with liquid chromatography, particularly at higher flow rates, the nebulizer is often positioned orthogonal to (or at a similarly steep angle to) the inlet of the mass spectrometer, so that solvent and neutral material does not contaminate the actual inlet of the mass spectrometer.

Sources: en.wikipedia.org

Notes from published material

=== Nematode === The genome of the nematode worm C. elegans contains 9 serpins, all of which lack signal sequences and so are likely intracellular. However, only 5 of these serpins appear to function as protease inhibitors. One, SRP-6, performs a protective function and guards against stress-induced calpain-associated lysosomal disruption. Further, SRP-6 inhibits lysosomal cysteine proteases released after lysosomal rupture. Accordingly, worms lacking SRP-6 are sensitive to stress. Most notably, SRP-6 knockout worms die when placed in water (the hypo-osmotic stress lethal phenotype or Osl). It has therefore been suggested that lysosomes play a general and controllable role in determining cell fate.

=== Gel === Gels are used as stationary phase for GPC. The pore size of a gel must be carefully controlled in order to be able to apply the gel to a given separation. Other desirable properties of the gel forming agent are the absence of ionizing groups and, in a given solvent, low affinity for the substances to be separated. Commercial gels like PLgel & Styragel (cross-linked polystyrene-divinylbenzene), LH-20 (hydroxypropylated Sephadex), Bio-Gel (cross-linked polyacrylamide), HW-20 & HW-40 (hydroxylated methacrylic polymer), and agarose gel are often used based on different separation requirements.

Upon oral ingestion, EMP is rapidly and completely dephosphorylated by phosphatases into estramustine during the first pass in the gastrointestinal tract. Estramustine is also partially but considerably oxidized into estromustine by 17β-hydroxysteroid dehydrogenases during the first pass. As such, EMP reaches the circulation as estramustine and estromustine, and the major metabolite of EMP is estromustine. A limited quantity of approximately 10 to 15% of estramustine and estromustine is further slowly metabolized via hydrolysis of the normustine ester into estradiol and estrone, respectively. This reaction is believed to be catalyzed by carbamidases, although the genes encoding the responsible enzymes have not been characterized. The circulating levels of normustine formed from EMP are insignificant. Release of nitrogen mustard gas from normustine via cleavage of the carboxylic acid group has not been demonstrated and does not seem to occur. The oral bioavailability of EMP is low, which is due to profound first-pass metabolism; specifically, dephosphorylation of EMP. The oral bioavailability of EMP specifically as estramustine and estromustine is 44 to 75%, suggesting that absorption may be incomplete. In any case, there is a linear relationship between the oral dose of EMP and circulating levels of estramustine and estromustine. Consumption of calcium, aluminium, or magnesium with oral EMP can markedly impair its bioavailability due to diminished absorption from the intestines, and this may interfere with its therapeutic effectiveness at low doses.

Many canids feed opportunistically on carrion. Examples include foxes such as the Arctic fox, corsac fox, gray fox, kit fox and red fox, hyenas such as the brown hyena, spotted hyena and striped hyena, black-backed jackals and golden jackals, as well as coyotes, culpeos, dingoes, gray wolves, Pampas zorros, and raccoon dogs. Types of carrion fed upon ranges from dead wildlife and dead livestock to abandoned predator kills and hunting discards. Anatomically and immunologically, canids are well-adapted to carrion feeding. For example, gray wolves hold food in their stomachs for at least twice as long as humans and other primates. This gives their gastric acid longer to kill pathogens before they enter the small intestine. The intestinal tracts of canids are also much shorter than those of primates, so pathogens have less time to multiply and cause disease prior to their expulsion. Anti-botulinum antibodies are an additional antibacterial defense detected in coyotes.

Sources: en.wikipedia.org

Frequently asked questions